SCHEMBL147193

SCHEMBL147193

CC(C)C(=O)CP(=O)(O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.46
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
BLM P54132 1/20 0.46
KMT2A Q03164 1/20 0.46
ENO1 P06733 1/20 0.40
PGK1 P00558 1/20 0.39
PGK2 P07205 1/20 0.39
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2B Q13224 1/20 0.38
GRIN2C Q14957 1/20 0.38
GRIN3A Q8TCU5 1/20 0.38
LAP3 P28838 4/20 0.37
ANPEP P15144 3/20 0.37
ERAP1 Q9NZ08 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21879799 0.81 CA2 (0.35) TDP1MEN1LMNAHPGDTSHR
SCHEMBL14617621 0.81 TDP1 (0.43) TDP1MEN1LMNAHPGDTSHR
SCHEMBL25448175 0.79 MMP1 (0.32) TDP1MEN1LMNAHPGDTSHR
SCHEMBL11118063 0.79 TDP1 (0.42) TDP1MEN1LMNAHPGDTSHR
SCHEMBL28640700 0.75 MMP1 (0.33) MMP1MMP8
SCHEMBL263667 0.74 LAP3 (0.42) TDP1MEN1LMNAHPGDTSHR
SCHEMBL2988737 0.74 ALDH1A1 (0.41) TDP1ANPEPALDH1A1
SCHEMBL12379164 0.74 CTSA (0.36) TDP1LAP3ALDH1A1
SCHEMBL3939887 0.72 PPARD (0.47) TDP1TSHRMMP1
SCHEMBL3939885 0.72 LMNA (0.31) LMNAMMP1MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400793-A1 COMPOSITION FOR POLYURETHANE FOAM, FOAM PREPARED THEREFROM AND A METHOD THEREOF MOMENTIVE PERFORMANCE MATERIALS INC. 2024-12-05 US claimed
EP-4396271-A1 COMPOSITION FOR POLYURETHANE FOAM, FOAM PREPARED THEREFROM AND A METHOD THEREOF Momentive Performance Materials Inc. (US) 2024-07-10 EP claimed
WO-2023034354-A1 COMPOSITION FOR POLYURETHANE FOAM, FOAM PREPARED THEREFROM AND A METHOD THEREOF MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2023-03-09 WO claimed
US-20120264011-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2012-10-18 US claimed
US-4338466-A PRECURSORS FOR OLIGOMERS EXHIBITING PROTECTION FOR OXIDATIVE PHOSPHORYLATION OF DEGENERATED MITOCHONDRIA THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 1982-07-06 US claimed
EP-4269400-B1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS MOLECURE SA (PL) 2025-07-09 EP disclosed
US-20250171402-A1 Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors UNIV NORTHWESTERN (US) 2025-05-29 US disclosed
US-12240815-B2 Potent and selective human neuronal nitric oxide synthase inhibitors NORTHWESTERN UNIVERSITY (US) 2025-03-04 US disclosed
US-20240400793-A1 COMPOSITION FOR POLYURETHANE FOAM, FOAM PREPARED THEREFROM AND A METHOD THEREOF MOMENTIVE PERFORMANCE MATERIALS INC. 2024-12-05 US disclosed
EP-4431492-A1 COMPOUND, COMPOSITION, METHOD, AND PRODUCTION METHOD Warrantee Inc. (JP) 2024-09-18 EP disclosed
EP-4396271-A1 COMPOSITION FOR POLYURETHANE FOAM, FOAM PREPARED THEREFROM AND A METHOD THEREOF Momentive Performance Materials Inc. (US) 2024-07-10 EP disclosed
US-11945797-B2 1-cyano-pyrrolidine derivatives as dub inhibitors MISSION THERAPEUTICS LIMITED (GB) 2024-04-02 US disclosed
EP-0537996-A1 Avermectin compounds with a 6,5-spiroketal ring system and a 23-acyl substituent MERCK & CO. INC. (US) 1993-04-21 EP disclosed
US-5171742-A Avermectin compounds with a 6,5-spiroketal ring system ad a 23-acyl substituent MERCK & CO., INC. (US) 1992-12-15 US disclosed
US-5169854-A N-substituted-furylalkenyl hydroxamic acid and N-hydroxyurea compounds having lipoxygenase inhibitory activity ABBOTT LABORATORIES (US) 1992-12-08 US disclosed
EP-0503885-A1 Avermectin compounds with a 6,5-spiroketal ring system MERCK & CO. INC. (US) 1992-09-16 EP disclosed
EP-0351214-A1 Anti-inflammatory aryl derivatives THE WELLCOME FOUNDATION LIMITED (GB) 1990-01-17 EP disclosed
US-4775692-A ANTILIPEMIC, ANTICOAGULANT, HYPOTENSIVE, ANTISECRETORY AND ANTIULCER AGENT TORAY INDUSTRIES, INC. (JP) 1988-10-04 US disclosed
EP-0210571-A1 Phosphonopyridines and their 1,4-dihydroderivatives BOEHRINGER BIOCHEMIA ROBIN S.p.A. (IT) 1987-02-04 EP disclosed
US-4073934-A Novel acetylenic prostaglandin analogs SCHERING AKTIENGESELLSCHAFT (DT) 1978-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11945797-B2 1-cyano-pyrrolidine derivatives as dub inhibitors USP30, USP28, USP1 TDP1 1839/4885MEN1 4229/4885LMNA 2089/4885
US-12240815-B2 Potent and selective human neuronal nitric oxide synthase inhibitors NOS2, NOS1, NOS3 TDP1 132/4885MEN1 2626/4885LMNA 1382/4885
US-20250171402-A1 Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors NOS2, NOS1, NOS3 TDP1 132/4885MEN1 2626/4885LMNA 1382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.